Dog study results
Extended-release bupivacaine has been studied in dog models as part of the development for human use. These studies were centered on the local and systemic safety and tolerability of the suspension in a dog model of inguinal hernia repair and reported similar macroscopic and microscopic findings in control and bupivacaine liposome injectable suspension-treated animals at day 15. There were no significant adverse effects on wound healing using bupivacaine liposome injectable suspension at doses higher than expected with clinical use in dogs.
This same group also investigated the effects of repeated doses of bupivacaine liposome injectable suspension in
dogs. Dogs were injected twice weekly for a total of eight injections with bupivacaine liposome injectable suspension (at doses higher than clinically recommended), bupivacaine HCl, or saline, administered into the subcutaneous tissue over the scapulae. There were no observed clinical signs consistent with CNS toxicity and no ECG abnormalities. In the bupivacaine liposome injectable suspension group, the only difference observed as compared to the other groups was macroscopic and microscopic indications of mild-to-moderate granulomatous inflammation. These observations were considered a normal response to the liposomes.
IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.
NOCITA is now available.
“We began using Nocita on patients undergoing cranial cruciate ligament stabilization surgeries and have been very pleased with the results. The product is intuitive to use and we have observed nothing but positive effects for our patients post-operatively. Specifically, these patients appear to bear more significant weight immediately post-op than usually expected, require very little rescue analgesia, and are willing to eat early in the recovery period which has allowed easy transition to oral medications. Nocita has quickly become standard protocol for analgesia on our cruciate ligament stabilization procedures.”Veterinary Surgeon
Other therapeutics from Aratana
ENTYCE (capromorelin oral solution) provides appetite stimulation.
Inappetence in dogs is a serious problem. Recently-FDA-approved ENTYCE provides safe, effective appetite stimulation.
IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.
GALLIPRANT® (gapriprant tablets)
for the control of pain and inflammation associated with osteoarthritis in dogs.
GALLIPRANT is a first-in-class piprant and a non-COX-inhibiting prostaglandin receptor antagonist (PRA). It specifically blocks the EP4 receptor, the primary mediator of canine OA pain and inflammation, and does not inhibit the production of many housekeeping prostanoids that maintain homeostatic functions.1
1Kirkby Shaw K, Rausch-Derra L, Rhodes L. Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci. 2016;2(1):3-9.
In co-promotion with Elanco
IMPORTANT SAFETY INFORMATION: Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If GALLIPRANT is used long term, appropriate monitoring is recommended. Concomitant use of GALLIPRANT with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of GALLIPRANT has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Please see the full Prescribing Information for more detail.